A detailed history of Guggenheim Capital LLC transactions in Amgen Inc stock. As of the latest transaction made, Guggenheim Capital LLC holds 246,694 shares of AMGN stock, worth $65.1 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
246,694
Previous 277,069 10.96%
Holding current value
$65.1 Million
Previous $86.6 Million 8.18%
% of portfolio
0.57%
Previous 0.62%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$309.38 - $337.38 $9.4 Million - $10.2 Million
-30,375 Reduced 10.96%
246,694 $79.5 Million
Q2 2024

Aug 14, 2024

SELL
$262.75 - $319.31 $3.08 Million - $3.74 Million
-11,710 Reduced 4.06%
277,069 $86.6 Million
Q1 2024

May 14, 2024

BUY
$268.87 - $324.56 $1.03 Million - $1.25 Million
3,839 Added 1.35%
288,779 $82.1 Million
Q4 2023

Feb 14, 2024

SELL
$255.7 - $288.46 $3.66 Million - $4.13 Million
-14,304 Reduced 4.78%
284,940 $82.1 Million
Q3 2023

Nov 14, 2023

BUY
$218.65 - $271.46 $1.65 Million - $2.05 Million
7,542 Added 2.59%
299,244 $80.4 Million
Q2 2023

Aug 11, 2023

BUY
$214.27 - $253.37 $5.82 Million - $6.89 Million
27,176 Added 10.27%
291,702 $64.8 Million
Q1 2023

May 10, 2023

BUY
$225.79 - $275.2 $5.36 Million - $6.53 Million
23,745 Added 9.86%
264,526 $63.9 Million
Q4 2022

Feb 14, 2023

SELL
$229.03 - $291.01 $9.81 Million - $12.5 Million
-42,846 Reduced 15.11%
240,781 $63.2 Million
Q3 2022

Nov 14, 2022

BUY
$224.46 - $253.15 $87,090 - $98,222
388 Added 0.14%
283,627 $63.9 Million
Q2 2022

Aug 15, 2022

SELL
$230.71 - $256.74 $8.04 Million - $8.95 Million
-34,851 Reduced 10.96%
283,239 $68.9 Million
Q1 2022

May 16, 2022

SELL
$219.27 - $242.57 $9.07 Million - $10 Million
-41,356 Reduced 11.51%
318,090 $76.9 Million
Q4 2021

Feb 14, 2022

BUY
$198.88 - $227.6 $9.48 Million - $10.8 Million
47,642 Added 15.28%
359,446 $80.9 Million
Q3 2021

Nov 15, 2021

BUY
$212.27 - $248.7 $993,211 - $1.16 Million
4,679 Added 1.52%
311,804 $66.3 Million
Q2 2021

Aug 13, 2021

BUY
$233.58 - $259.14 $5.83 Million - $6.47 Million
24,963 Added 8.85%
307,125 $74.9 Million
Q1 2021

May 13, 2021

SELL
$221.91 - $258.6 $6.28 Million - $7.32 Million
-28,299 Reduced 9.12%
282,162 $70.2 Million
Q4 2020

Feb 16, 2021

BUY
$216.38 - $257.67 $5.06 Million - $6.02 Million
23,368 Added 8.14%
310,461 $71.4 Million
Q3 2020

Nov 13, 2020

SELL
$234.65 - $260.95 $6.31 Million - $7.01 Million
-26,880 Reduced 8.56%
287,093 $73 Million
Q2 2020

Aug 14, 2020

BUY
$197.81 - $242.74 $10.3 Million - $12.7 Million
52,267 Added 19.97%
313,973 $74.1 Million
Q1 2020

Jun 02, 2020

SELL
$182.24 - $241.7 $12.9 Million - $17.1 Million
-70,834 Reduced 21.3%
261,706 $53.1 Million
Q4 2019

Feb 14, 2020

BUY
$189.21 - $243.2 $5.71 Million - $7.33 Million
30,153 Added 9.97%
332,540 $80.2 Million
Q3 2019

Nov 14, 2019

SELL
$174.11 - $208.62 $73,474 - $88,037
-422 Reduced 0.14%
302,387 $58.5 Million
Q2 2019

Aug 14, 2019

SELL
$166.7 - $195.41 $1.89 Million - $2.21 Million
-11,312 Reduced 3.6%
302,809 $55.8 Million
Q1 2019

May 15, 2019

BUY
$180.87 - $203.88 $2.67 Million - $3.01 Million
14,785 Added 4.94%
314,121 $59.7 Million
Q4 2018

Feb 14, 2019

SELL
$178.4 - $208.25 $9.62 Million - $11.2 Million
-53,937 Reduced 15.27%
299,336 $58.3 Million
Q3 2018

Nov 14, 2018

SELL
$185.29 - $208.89 $5.68 Million - $6.41 Million
-30,674 Reduced 7.99%
353,273 $73.2 Million
Q2 2018

Aug 14, 2018

SELL
$166.05 - $186.51 $51.6 Million - $57.9 Million
-310,604 Reduced 44.72%
383,947 $70.9 Million
Q1 2018

May 15, 2018

SELL
$169.43 - $198.0 $6.73 Million - $7.86 Million
-39,715 Reduced 5.41%
694,551 $118 Million
Q4 2017

Feb 14, 2018

BUY
$168.79 - $188.59 $1.85 Million - $2.07 Million
10,980 Added 1.52%
734,266 $128 Million
Q3 2017

Nov 14, 2017

BUY
$167.29 - $191.0 $121 Million - $138 Million
723,286
723,286 $135 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.